Success Metrics

Clinical Success Rate
86.1%

Based on 179 completed trials

Completion Rate
86%(179/208)
Active Trials
4(2%)
Results Posted
54%(96 trials)
Terminated
29(12%)

Phase Distribution

Ph phase_2
24
10%
Ph phase_3
74
30%
Ph phase_1
16
7%
Ph phase_4
95
39%
Ph not_applicable
25
10%
Ph early_phase_1
1
0%

Phase Distribution

17

Early Stage

24

Mid Stage

169

Late Stage

Phase Distribution235 total trials
Early Phase 1First-in-human
1(0.4%)
Phase 1Safety & dosage
16(6.8%)
Phase 2Efficacy & side effects
24(10.2%)
Phase 3Large-scale testing
74(31.5%)
Phase 4Post-market surveillance
95(40.4%)
N/ANon-phased studies
25(10.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.5%

179 of 217 finished

Non-Completion Rate

17.5%

38 ended early

Currently Active

4

trials recruiting

Total Trials

245

all time

Status Distribution
Active(6)
Completed(179)
Terminated(38)
Other(22)

Detailed Status

Completed179
Terminated29
unknown22
Withdrawn9
Recruiting4
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
245
Active
4
Success Rate
86.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.4%)
Phase 116 (6.8%)
Phase 224 (10.2%)
Phase 374 (31.5%)
Phase 495 (40.4%)
N/A25 (10.6%)

Trials by Status

terminated2912%
withdrawn94%
not_yet_recruiting21%
unknown229%
completed17973%
recruiting42%

Recent Activity

Clinical Trials (245)

Showing 20 of 245 trialsScroll for more
NCT00365859Phase 3

Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)

Completed
NCT06969755Phase 4

Biomarkers to Enhance Early Schizophrenia Treatment

Recruiting
NCT07565428Phase 3

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Recruiting
NCT00232687Phase 4

A Switch Study of BMS-337039 in Schizophrenic Out-patients

Completed
NCT02977299Phase 4

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

Completed
NCT00102479Phase 1

Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

Completed
NCT07483294Phase 4

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Recruiting
NCT00044655Phase 4

Switching Medication to Treat Schizophrenia

Completed
NCT00337571Phase 3

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Completed
NCT00332241Phase 3

Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD).

Completed
NCT07550387Phase 2

A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia

Completed
NCT03485417Phase 2

Substance Misuse To Psychosis for Stimulants

Completed
NCT05814640Phase 1

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

Recruiting
NCT06236451Phase 4

Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia

Completed
NCT05545891Phase 2

Aripiprazole in Body Focused Repetitive Behaviors

Not Yet Recruiting
NCT02634463Phase 1

Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

Completed
NCT01490086Phase 2

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Completed
NCT07011693Phase 4

Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I)

Not Yet Recruiting
NCT02431702Phase 3

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Completed
NCT03874494Phase 3

Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia

Completed

Drug Details

Intervention Type
DRUG
Total Trials
245